New clinical recommendations detail updated vaccination and screening protocols to reduce infection and cancer risks in adults with inflammatory bowel disease, particularly those on immune-modifying therapies.
A new multicenter trial found that self-injected low-dose triamcinolone using an assistance device was as effective and safe as physician-administered injections for inflammatory acne, with improved outcomes at higher doses for severe lesions.
The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.
Researchers uncovered how herpes simplex virus type 1 reprograms human chromatin structure by hijacking transcriptional machinery, potentially revealing a new antiviral target.